Assessment of Treatment Satisfaction in Psoriasis
银屑病治疗满意度评估
基本信息
- 批准号:10657012
- 负责人:
- 金额:$ 20.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-01 至 2023-07-14
- 项目状态:已结题
- 来源:
- 关键词:AdherenceAdverse effectsAffectBehaviorCaliforniaChronic small plaque psoriasisClient satisfactionClinicalClinical TrialsClinical Trials DesignConsensusDermatologicDermatologyDevelopmentEffectivenessEvaluationFlareFutureGenerationsGoalsInternationalInterviewMeasurementMeasuresMethodologyOutcomeOutcome MeasurePatient Outcomes AssessmentsPatient-Centered CarePatientsPharmaceutical PreparationsPrediction of Response to TherapyProcessPsoriasisReportingResearchResearch PersonnelSamplingSigns and SymptomsSkinStructureTestingTherapeutic StudiesTreatment ProtocolsTreatment outcomeUnited States National Institutes of HealthWorkcare deliveryclinical decision-makingclinical practicecohortdesignexperienceimprovedinstrumentmedication compliancenoveloptimal treatmentspatient populationprospectiverecruitsatisfactionshared decision makingside effectsuccesssystematic reviewtherapeutic candidatetreatment adherencetreatment pattern
项目摘要
PROJECT SUMMARY / ABSTRACT
Treatments for plaque psoriasis vary substantially in effectiveness and side effects. It is often difficult to
determine the optimal treatment during a patient-centric, shared decision-making process between the
clinician and patient. The NIH and other stakeholders consider patient-reported outcomes (PROs) crucial for
the support of patient-centered care because PROs reflect the patients’ perspective and offer important
information to improve clinical decision-making and care delivery.
Treatment satisfaction is a key PRO that represents the patient’s experience with the process and outcome
of the treatment. Patient satisfaction with their treatment is critical because it affects patients’ treatment-
related behaviors, such as the likelihood of continuing to use their medication, to use the medication
correctly, and to adhere to prescribed treatment regimens. These treatment-related behaviors, in turn,
substantially impact the success of treatment outcomes.
The overarching goal of this study is to validate a patient-reported, dermatology-specific treatment
satisfaction instrument (DermSat). In this study, we plan to achieve two aims. In Aim 1, we will validate
DermSat for longitudinal assessment of patient satisfaction with psoriasis treatments during stable psoriasis
and flares. We will also determine if DermSat will confer good reliability. We will study this aim in a
prospective, observational cohort and recruit from a diverse psoriasis patient population in southern
California.
In Aim 2, we will determine whether DermSat predicts medication adherence and treatment changes.
Specifically, we will evaluate the predictive validity of DermSat by examining the relationship between
DermSat and subsequent assessment of adherence and treatment changes. A measure with excellent
predictive validity will enable clinicians to identify treatment dissatisfaction and intervene earlier to minimize
the long-term impact of psoriasis.
The successful completion of this research will lead to the first valid and reliable dermatology-specific
treatment satisfaction instrument. The study findings will have a marked impact on future clinical trial
design. DermSat will address the critical need to capture patients’ treatment experience in studies for both
approved and investigative dermatological therapies. Valid assessment of patients’ treatment satisfaction
will also help inform shared decision-making between clinicians and patients in clinical practice, predict
treatment adherence, and improve the likelihood of long-term treatment success.
项目总结/摘要
治疗斑块型银屑病的有效性和副作用差异很大。往往很难
在以患者为中心的共享决策过程中确定最佳治疗,
临床医生和患者。NIH和其他利益相关者认为患者报告的结果(PRO)对于
支持以病人为中心的护理,因为PRO反映了病人的观点,
信息,以改善临床决策和护理服务。
治疗满意度是一个关键的PRO,代表了患者对过程和结果的体验
的治疗。患者对治疗的满意度至关重要,因为这会影响患者的治疗-
相关行为,例如继续使用药物的可能性,使用药物
正确,并坚持规定的治疗方案。这些与治疗相关的行为,反过来,
对治疗结果的成功有很大影响。
本研究的首要目标是验证患者报告的皮肤科特异性治疗
满意度测量仪(DermSat)在这项研究中,我们计划实现两个目标。在目标1中,我们将验证
DermSat用于银屑病稳定期患者对银屑病治疗满意度的纵向评估
和照明弹。我们还将确定DermSat是否具有良好的可靠性。我们将在一个
前瞻性、观察性队列研究,并从南方不同银屑病患者人群中招募
加州。
在目标2中,我们将确定DermSat是否能预测药物依从性和治疗变化。
具体来说,我们将通过检查以下因素之间的关系来评估DermSat的预测有效性:
DermSat和随后的依从性和治疗变化评估。一个很好的衡量标准,
预测有效性将使临床医生能够识别治疗不满意,并尽早干预,以最大限度地减少
牛皮癣的长期影响
这项研究的成功完成将导致第一个有效和可靠的皮肤科特异性
治疗满意度量表研究结果将对未来的临床试验产生显著影响
设计DermSat将满足在研究中获取患者治疗经验的关键需求,
批准和研究性皮肤病治疗。患者治疗满意度的有效评估
还将有助于在临床实践中告知临床医生和患者之间的共同决策,预测
治疗依从性,并提高长期治疗成功的可能性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
April W Armstrong其他文献
Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Janus激酶抑制剂在皮肤病学中的应用:综述其在银屑病、白癜风、系统性红斑狼疮、化脓性汗腺炎、皮肌炎、扁平苔藓、扁平苔藓、结节病和移植物抗宿主病中的应用。
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
Margaret Y. Huang;April W Armstrong - 通讯作者:
April W Armstrong
Shared decision-making in psoriasis care: Evaluation of how patients’ perception of clinicians’ delivery of care changes by age and sex
银屑病护理中的共同决策:评估患者对信徒提供护理的看法如何随年龄和性别而变化
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:3.7
- 作者:
Robin Kikuchi;Paige Kingston;Audrey Hao;Kaviyon Sadrolashrafi;Rebecca K Yamamoto;Hannah C Tolson;Sara N Bilimoria;Lily Guo;Danielle K Yee;Maria T Ochoa;April W Armstrong - 通讯作者:
April W Armstrong
Prevalence, Incidence, and Risk of Chronic Obstructive Pulmonary Disease Among Psoriasis Patients.
银屑病患者慢性阻塞性肺疾病的患病率、发病率和风险。
- DOI:
10.1016/j.rmed.2024.107729 - 发表时间:
2024 - 期刊:
- 影响因子:4.3
- 作者:
Lily Guo;Sara N Bilimoria;Robin Kikuchi;Audrey Hao;Hannah Tolson;Rebecca K Yamamoto;Kaviyon Sadrolashrafi;Danielle Yee;April W Armstrong - 通讯作者:
April W Armstrong
April W Armstrong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('April W Armstrong', 18)}}的其他基金
Team-Based Connected Health to Improve Access and Outcomes in Atopic Dermatitis
基于团队的互联健康可改善特应性皮炎的可及性和结果
- 批准号:
10341132 - 财政年份:2019
- 资助金额:
$ 20.03万 - 项目类别:
Team-Based Connected Health to Improve Access and Outcomes in Atopic Dermatitis
基于团队的互联健康可改善特应性皮炎的可及性和结果
- 批准号:
10552028 - 财政年份:2019
- 资助金额:
$ 20.03万 - 项目类别:
Patient-Centered Online Care Model for Follow-Up Management of Atopic Dermatitis
以患者为中心的特应性皮炎后续管理在线护理模式
- 批准号:
8507613 - 财政年份:2009
- 资助金额:
$ 20.03万 - 项目类别:
Patient-Centered Online Care Model for Follow-Up Management of Atopic Dermatitis
以患者为中心的特应性皮炎后续管理在线护理模式
- 批准号:
7941834 - 财政年份:2009
- 资助金额:
$ 20.03万 - 项目类别:
Patient-Centered Online Care Model for Follow-Up Management of Atopic Dermatitis
以患者为中心的特应性皮炎后续管理在线护理模式
- 批准号:
8107608 - 财政年份:2009
- 资助金额:
$ 20.03万 - 项目类别:
Patient-Centered Online Care Model for Follow-Up Management of Atopic Dermatitis
以患者为中心的特应性皮炎后续管理在线护理模式
- 批准号:
8791378 - 财政年份:2009
- 资助金额:
$ 20.03万 - 项目类别:
Patient-Centered Online Care Model for Follow-Up Management of Atopic Dermatitis
以患者为中心的特应性皮炎后续管理在线护理模式
- 批准号:
7781767 - 财政年份:2009
- 资助金额:
$ 20.03万 - 项目类别:
Patient-Centered Online Care Model for Follow-Up Management of Atopic Dermatitis
以患者为中心的特应性皮炎后续管理在线护理模式
- 批准号:
8298923 - 财政年份:2009
- 资助金额:
$ 20.03万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 20.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 20.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 20.03万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 20.03万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 20.03万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 20.03万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 20.03万 - 项目类别:
Studentship














{{item.name}}会员




